Characteristics of young illicit drug injectors who use North America's first medically supervised safer injecting facility

Addiction Research and Theory

Volumn 15, Issue 1, 2007, Pages 63-69

  Stoltz, Jo Anne M ^a   Wood, Evan ^a,b   Miller, Cari ^a   Small, Will ^a   Li, Kathy ^a   Tyndall, Mark ^a,b   Montaner, Julio ^a,b   Kerr, Thomas ^a  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

HIV AIDS; Injection drug use; Safer injecting facility; Youth

Indexed keywords

EID: 33947417012     PISSN: 16066359     EISSN: 14767392     Source Type: Journal    
DOI: 10.1080/16066350601081090     Document Type: Article

References (34)

1. Bourgois P, Lettier M, Quesada J. 1997. Social misery and the sanctions of substance abuse: Confronting HIV risk among homeless heroin addicts in San Francisco. Social Problems 44:155-173.
2. Bundesministerium fur Gesundheit und Soziale Sicherung. 2003. Evaluation der Arbeit von Drogenkonsumauen in der Bundesrepulik Deutschland. Baden-Baden: Nomos.
3. Burns JM, Martyres RF, Clode D, Boldero JM. 2004. Overdose in young people using heroin: Associations with mental health, prescription drug use and personal circumstances. Medical Journal of Australia 181:825-828.
4. CDCP. 2003. HIV/AIDS among youth. Washington, DC: Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention.
5. Craib KJ, Spittal PM, Wood E, LaLiberte N, Hogg RS, Li K, et al. 2003. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. Canadian Medical Association Journal 168: 19-24.
6. Culhane DP, Gollub E, Kuhn R, Shpaner M. 2001. The co-occurrence of AIDS and homelessness: Results from the integration of administrative databases for AIDS surveillance and public shelter utilisation in Philadelphia. Journal of Epidemiology and Community Health 55:515-520.
7. Dematteo D, Major C, Block B, Coates R, Fearon M, Goldberg E, et al. 1999. Toronto street youth and HIV/Aids: Prevalence, demographics, and risks. Journal of Adolescent Health 25:358-366.
8. de Jong W, Wever U. 1999. The professional acceptance of drug use: A closer look at drug consumption rooms in the Netherlands, Germany, and Switzerland. International Journal of Drug Policy 10:99-108.
9. Diaz T, Des Jarlais DC, Vlahov D, Perlis TE, Edwards V, Friedman SR, et al. 2001. Factors associated with prevalent hepatitis C: Differences among young adult injection drug users in lower and upper Manhattan, New York City. American Journal of Public Health 91:23-30.
10. Fuller CM, Absalon J, Ompad DC, Nash D, Koblin B, Blaney S, et al. 2005. A comparison of HIV seropositive and seronegative young adult heroin- and cocaine-using men who have sex with men in New York City, 2000-2003. Journal of Urban Health 82:i51-i61.
11. Hahn JA, Page-Shafer K, Lum PJ, Ochao K, Moss AR. 2001. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 34:180-187.
12. Health Canada. 2005. HIV Epi Updates. Ottawa, Ontario: Surveillance and Risk Assessment Division, Centre for Infectious Disease Control, Public Health Agency of Canada.
13. Kemmesies, UE. 1999. Final report: The open drug scene and the safe injection room offers in Frankfurt am Main.
14. Kilbourne AM, Herndon B, Anderson RM, Wenzel SL, Gelberg L. 2002. Psychiatric symptoms, health services, and HIV risk factors among homeless women. Journal of Health Care for the Poor Underserved 13:49-65.
15. Miller CL, Johnston C, Spittal PM, Li K, LaLiberte N, Montaner JS, et al. 2002a. Opportunities for prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 36:737-742.
16. Miller CL, Spittal P, Frankish JC, Li K, Schecter MT, Wood E. 2004a. Binge drug use independently predicts HIV seroconversion among injection drug users: Implications for public health strategies. 13th Annual Canadian Conference on HIV/AIDS Research, Montreal, Canada.
17. Miller CL, Spittal P, LaLiberte N, Li K, Tyndall MW, O'Shaughnessy MV, et al. 2002b. Females experiencing sexual and drug vulnerabilities are at elevated risk for HIV infection among youth who use injection drugs. Journal of Acquired Immune Deficiency Syndrome 30:335-341.
18. Miller CL, Tyndall M, Spittal P, Li K, Palepu A, Schecter MT. 2002c. HIV incidence and associated risk factors among young injection drug users. AIDS 16:491-493.
19. Miller CL, Wood E, Spittal PM, Li K, Frankish JC, Braitstein P, et al. 2004b. The future face of coinfection: Prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. Journal of Acquired Immune Deficiency Syndromes 36:743-749.
20. Ochoa KC, Davidson PJ, Evans JL, Hahn JA, Page-Shafer K, Moss, AR. 2005. Heroin overdose among young injection drug users in San Francisco. Drug and Alcohol Dependence 80:297-302.
21. Palepu A, Tyndall MW, Leon H, Muller J, O'Shaugnessy MV, Schecter MT, et al. 2001. Hospital utilization and costs in a cohort of injection drug users. Canadian Medical Association Journal 165:415-420.
22. Regidor E, de la Fuente L, Calle ME, Navarro P, Dominguez V. 2003. Unusually strong association between education and mortality in young adults in a community with a high rate of injection-drug users. European Journal of Public Health 13:334-339.
23. Roy E, Haley N, Leclerc P, Sochanski B, Boudreau JF, Boivin JF. 2004. Mortality in a cohort of street youth in Montreal. Journal of the American Medical Association 292:569-574.
24. Spittal PM, Craib KJ, Wood E, LaLiberte N, Li K, Tyndall MW, et al. 2002. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. Canadian Medical Association Journal 166:894-899.
25. Strathdee SA, Patrick DM, Currie SL, et al. 1997. Needle exchange is not enough: Lessons from the Vancouver injecting drug use study. AIDS 11:F59-F65.
26. Tyndall MW, Currie S, Spittal P, Li K, Wood E, O'Shaughnessy MV, et al. 2003. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 17:887-893.
27. Wall R, Rehm J, Fischer B, Brands B, Gliksman L, Steward J, Medved W, et al. 2000. Social costs of untreated opioid dependence. Journal of Urban Health 77:688-722.
28. Wood E, Kerr T, Lloyd-Smith E, Buchner C, Marsh DC, Montaner JS, Tyndall MW. 2004a. Methodology for evaluating Insite: Canada. Harm Reduction Journal 1:9.
29. Wood E, Kerr T, Montaner JS, Strathdee SA, Wodak A, Hankins CA, et al. 2004b. Rationale for evaluating North America. Lancet Infectious Disease 4:301-306.
30. Wood E, Kerr T, Spittal P, Li K, Small W, Tyndall MW, et al. 2003. The potential public health and community impacts of safer injecting facilities: Evidence from a cohort of injection drug users. Journal of Acquired Immune Deficiency Syndromes 32:2-8.
31. Wood E, Schechter MT, Tyndall MW, Montaner JS, O'Shaughnessy MV, Hogg RS. 2000. Antiretroviral medication use among injection drug users: Two potential futures. AIDS 14:1229-1235.
32. Wood E, Tyndall M, Spittal P, Li K, Hogg R, O'Shaugnessy MV, et al. 2002. Needle exchange and difficulty with needle access during an ongoing HIV epidemic. International Journal of Drug Policy 13:95-102.
33. Wood E, Tyndall M, Li K, Small W, Montaner JS, Kerr T. 2005. Do supervised injecting facilities attract higher-risk injection drug users? American Journal of Preventive Medicine 29:126-130.
34. Wood E, Tyndall MW, Spittal P, Li K, Kerr T, Hogg RS, et al. 2001. Unsafe injection practices in a cohort of injection drug users in Vancouver: Could safer injecting rooms help? Canadian Medical Association Journal 165:405-410.